Technology ID
TAB-3539
RALDH1 Inhibitors for the Immunotherapy of Hepatocellular Carcinoma
E-Numbers
E-041-2021-0
Lead Inventor
Rai Bantukallu, Ganesha (NCATS)
Co-Inventors
Yang, Shyh-Ming (NCATS)
Martinez, Natalia (NCATS)
Simeonov, Anton (NCATS)
Yasgar, Adam (NCATS)
Zakharov, Alexey (NCATS)
Haldar, Malay (University of Pennsylvania)
Applications
Therapeutics
Therapeutic Areas
Oncology
Lead IC
NCATS
ICs
NCATS
This technology includes the utility of the novel small molecule inhibitors of ALDH1A1 (RALDH1) in combination with immunotherapy for the treatment of hepatocellular carcinoma (HCC). Recently it was shown that the ALDH1A1 catalyzed production of retinoic acid (RA) in tumor cells promotes their differentiation into immunosuppressive antigen-presenting cells. Therefore, blocking RA production by tumor cells and/or blocking RA signaling in monocytes using our ALDH1A1 inhibitors can alleviate immunosuppression and engender anti-tumor immune responses.
Commercial Applications
Treatment of hepatocellular carcinoma and other solid tumors where the RA-based immune evasion pathway is active.
Competitive Advantages
First approach to combine ALDH1A1 inhibitors with cancer immunotherapy.
Licensing Contact: